Medicus Pharma (MDCX) announces topline results from its Phase 2 clinical study evaluating safety and efficacy of Doxorubicin Microneedle Array, D-MNA, to non-invasively treat basal cell carcinoma of the skin. The Company believes the topline results are not only positive but decision-grade that should support an end of phase 2 meeting with the FDA in the first half of 2026 as well as accelerate partnering readiness. “We are extremely encouraged by these topline results, which not only validate management’s scientific and investment thesis, but also provide what we consider to be decision-grade evidence of clinical activity, particularly at the 200-microgram dose level,” said Dr. Raza Bokhari, Executive Chairman & CEO of Medicus.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDCX:
- Medicus Pharma Showcases SkinJect and Teverelix Strategy at Roth Conference
- Medicus Pharma Wins FDA Go-Ahead for Phase 2b Teverelix Trial in High-Risk Prostate Cancer
- Medicus signs six-part media series with New to the Street
- Medicus receives FDA ‘study may proceed’ clearance for Teverelix Phase 2b study
- Medicus Pharma Lowers Teverelix Royalty Burden in Amended LifeArc License